Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177728
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pascual, Tomás | - |
dc.contributor.author | Oliveira, Mafalda | - |
dc.contributor.author | Ciruelos, Eva | - |
dc.contributor.author | Bellet Ezquerra, Meritxell | - |
dc.contributor.author | Saura, Cristina | - |
dc.contributor.author | Gavilá, Joaquin | - |
dc.contributor.author | Pernas, Sònia | - |
dc.contributor.author | Muñoz Mateu, Montserrat | - |
dc.contributor.author | Vidal Losada, Maria Jesús | - |
dc.contributor.author | Margelí Vila, Mireia | - |
dc.contributor.author | Cejalvo Andújar, Juan Miguel | - |
dc.contributor.author | González Farré, Blanca | - |
dc.contributor.author | Espinosa Bravo, Martin | - |
dc.contributor.author | Cruz, Josefina | - |
dc.contributor.author | Salvador Bofill, Francisco Javier | - |
dc.contributor.author | Guerra, Juan Antonio | - |
dc.contributor.author | Luna Barrera, Ana María | - |
dc.contributor.author | Arumi de Dios, Miriam | - |
dc.contributor.author | Esker, Stephen | - |
dc.contributor.author | Fan, Pang-dian | - |
dc.contributor.author | Martínez Sáez, Olga | - |
dc.contributor.author | Villacampa, Guillermo | - |
dc.contributor.author | Paré, Laia | - |
dc.contributor.author | Ferrero Cafiero, Juan M. | - |
dc.contributor.author | Villagrasa, Patricia | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.date.accessioned | 2021-05-28T09:50:37Z | - |
dc.date.available | 2021-05-28T09:50:37Z | - |
dc.date.issued | 2021-04-23 | - |
dc.identifier.uri | http://hdl.handle.net/2445/177728 | - |
dc.description.abstract | Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecular biology, tumor microenvironment, and mechanisms of drug resistance in breast cancer, we designed this window-of-opportunity study with the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402). Trial Design: Based on these data, a prospective, multicenter, single-arm, window-of-opportunity study was designed to evaluate the biological effect of patritumab deruxtecan in the treatment of naïve patients with HR-positive/HER2-negative early breast cancer whose primary tumors are ≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The primary endpoint is a CelTIL score after one single dose. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media S. A. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.638482 | - |
dc.relation.ispartof | Frontiers in Oncology, 2021 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2021.638482 | - |
dc.rights | cc by (c) Pascual et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Receptors d'hormones | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Hormone receptors | - |
dc.title | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-05-27T12:51:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33968735 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-11-638482.pdf | 2.38 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License